Pfizer Limited Bombay S.E.

PFIZER

INE182A01018

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-06-21 am EDT			5-day change	1st Jan Change
4,639 ^INR	-3.19%		-4.00%	+8.67%

May. 30	Pfizer Limited Receives an Order Issued by the Joint Commissioner of Sate Tax, Raipur Division 1: Chhattisgarh	CI
May. 17	Pfizer Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Pfizer Ltd. Wins Multiple Awardees Contract from The Common Services Agency

January 10, 2016 at 05:17 pm EST

Pfizer Ltd. won a GBP 12.4 million (excluding VAT) multiple awardees contract award from The Common Services Agency for the supply of a range of analgesic, anaesthetic, musculoskeletal, and joint disease medicines. This Framework Agreement is for the supply of a range of Analgesic, Anaesthetic, Musculoskeletal and Joint Disease Medicines to NHS Scotland.

Latest news about Pfizer Limited

Pfizer Limited Receives an Order Issued by the Joint Commissioner of Sate Tax, Raipur Division 1: Chhattisgarh	May. 30	CI
Pfizer Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 17	CI
Pfizer Limited has Received an Order Issued by the Assistant Commissioner, GST & Central Excise, Bhubaneswar-II Division Bhubaneswar	May. 02	CI
Pfizer Limited Receives Order from Deputy Commissioner, Dehradun - Sector 8: Uttarakhand	Apr. 25	CI
Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer	Apr. 02	CI
Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director Finance	Apr. 02	CI
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28	CI
Pfizer Limited Receives an Order from Joint Commissioner of State Tax Basis the GST Audit Conducted for Uttar Pradesh State for the Financial Year 2018-19	Mar. 22	CI
Pfizer Limited Receives an Order from Deputy Commissioner of State Tax Basis the GST Audit Conducted for the Financial Year 2018-19	Mar. 19	CI
Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024	Feb. 09	CI
Pfizer Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 09	CI
Pfizer Ltd. Names CFO	Jan. 21	MT
Pfizer CFO Retires	Dec. 01	MT
Pfizer Limited Announces Retirement of Mr. Milind Patil as Chief Financial Officer	Nov. 30	CI
Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023	Nov. 16	CI
Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023	Nov. 13	CI
Pfizer Sees Sharp Fall in Fiscal Q2 Net Profit	23-10-30	MT
Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors	23-10-28	CI
Pfizer Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-28	CI
Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead	23-09-06	CI
Pfizer Limited Announces Change in Management, Effective September 1, 2023	23-08-18	CI
Seagen's breast cancer therapy meets main goal in late-stage study	23-08-16	RE
Pfizer Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections	23-05-18	CI
Pfizer Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-15	CI

Chart Pfizer Limited

Duration

Period

More charts

Company Profile

Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Pfizer Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals

Pfizer Limited Bombay S.E.

Equities

PFIZER

INE182A01018

Pharmaceuticals

Pfizer Ltd. Wins Multiple Awardees Contract from The Common Services Agency

Latest news about Pfizer Limited

Chart Pfizer Limited

Company Profile

Income Statement Evolution

Ratings for Pfizer Limited

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals